SCHEMBL3356470

SCHEMBL3356470

Cc1ccc(CNCCCN(O)C(=O)O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.56
HDAC3 O15379 3/20 0.50
HDAC4 P56524 3/20 0.50
HDAC1 Q13547 3/20 0.50
HDAC7 Q8WUI4 3/20 0.50
HDAC2 Q92769 3/20 0.50
HDAC10 Q969S8 3/20 0.50
HDAC11 Q96DB2 3/20 0.50
HDAC8 Q9BY41 3/20 0.50
HDAC6 Q9UBN7 3/20 0.50
HDAC9 Q9UKV0 3/20 0.50
HDAC5 Q9UQL6 3/20 0.50
KDM6B O15054 1/20 0.49
KDM4A O75164 1/20 0.49
KDM2A Q9Y2K7 1/20 0.49
TMEM97 Q5BJF2 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
CCR6 P51684 1/20 0.44
PAX8 Q06710 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Toluene SCHEMBL3916489 0.96 CHRM2 (0.51) CHRM2HDAC3HDAC4HDAC1HDAC7
SCHEMBL3357890 0.84 CHRM2 (0.59) CHRM2KDM6BKDM4AKDM2ASIGMAR1
Toluene SCHEMBL3905099 0.84 MEN1 (0.55) CHRM2HDAC3HDAC1HDAC2HDAC8
SCHEMBL3351112 0.81 KDM6B (0.46) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL3353121 0.80 CHRM2 (0.62) CHRM2HDAC3HDAC1HDAC2HDAC8
Toluene SCHEMBL3903419 0.80 FOLH1 (0.46) HDAC3HDAC1HDAC2HDAC8KDM6B
Toluene SCHEMBL3909886 0.79 CHRM2 (0.54) CHRM2MEN1KMT2ANPC1TP53
Toluene SCHEMBL3916407 0.78 REN (0.51) SIGMAR1MEN1KMT2ANPC1RAB9A
Toluene SCHEMBL3910413 0.78 REN (0.55) SIGMAR1REN
SCHEMBL3350267 0.78 SCN8A (0.50) KDM6BKDM4AKDM2ACCR6PAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP CHRM2 876/4885HDAC3 527/4885HDAC4 1634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.